# Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma

> **NCT01149122** · PHASE3 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 266 (actual)

## Conditions studied

- Unresectable, Metastatic Biliary Tract Carcinoma

## Interventions

- **DRUG:** Gemcitabine/Oxaliplatin
- **DRUG:** Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)

## Key facts

- **NCT ID:** NCT01149122
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-06
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149122, "Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01149122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*